Ascletis Doses First Participants With ASC30

|January 26, 2026

4.0

Relevance Score

Ascletis Doses First Participants With ASC30 — Photo: cdn4.premiumread.com · rights & takedowns

Ascletis has dosed first participants in a 13-week U.S. Phase II study of ASC30, an oral small-molecule GLP-1R agonist for diabetes; topline data are expected in the third quarter of 2026.

Scoring Rationale

Progression to Phase II indicates moderate industry relevance, but RSS-only release provides limited details and constrains impact assessment.

Practice with real Health & Insurance data

90 SQL & Python problems · 15 industry datasets

Used by DS/ML engineers at top companies

Active PPO Plans with Rx CoverageEasy

Approved High-Value ClaimsMedium

Denial Rate by Plan TypeHard

250 free problems · No credit card

See all Health & Insurance problems

More AI & Data Science News

Anker debuts earbuds with on-device AI chip

6.3

May 22

News on Let's Data Science is compiled from multiple public sources with editorial oversight. See our Editorial Standards and Corrections Policy.

Scoring Rationale

More AI & Data Science News

Anker debuts earbuds with on-device AI chip

Pasqal Benchmarks Logical Qubits Against Physical

Researchers Uncover SEO-Poisoned Sites Delivering Infostealers

Kawasaki Establishes Physical AI Center with Nvidia and Partners

Scoring Rationale

More AI & Data Science News

Anker debuts earbuds with on-device AI chip

Pasqal Benchmarks Logical Qubits Against Physical

Researchers Uncover SEO-Poisoned Sites Delivering Infostealers

Kawasaki Establishes Physical AI Center with Nvidia and Partners